Deals channel feed

Astel­las buys in­to Fre­quen­cy's re­gen­er­a­tive med strat­e­gy with a $625M al­liance on hear­ing loss

6 years ago

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

6 years ago

Roche's Genen­tech goes on deal spree, un­veil­ing third deal on the same day

6 years ago

Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

6 years ago
Discovery

Deal hun­gry So­sei Hep­tares brings Roche's Genen­tech on board as a part­ner

6 years ago

Boehringer buys Swiss biotech in its lat­est M&A deal, go­ing the next-gen can­cer vac­cine route

6 years ago

Ab­b­Vie beefs up the on­col­o­gy pipeline, bag­ging an up­start STING play­er with its own unique ap­proach

6 years ago

Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

6 years ago
R&D
Pharma

KRAS G12C is the hot new play in can­cer R&D, and No­var­tis jumps in with a com­bo deal

6 years ago
R&D

Cel­gene turns to Nim­bus on ‘high­ly prized’ I/O tar­get — land­ing right in Bris­tol-My­ers’ sweet spot

6 years ago

More de­lays? Now Roche’s CEO says he’s will­ing to wait well in­to next year to com­plete their $4.3B Spark buy­out

6 years ago

Fat­ten­ing the bankroll, Bill Haney adds can­cer R&D pow­er­house Mer­ck to Sky­hawk's ros­ter of part­ners out to drug RNA

6 years ago
R&D

J&J dumps $915M de­vel­op­ment deal with Han­mi as an­oth­er Big Phar­ma aban­dons dis­as­ter-prone Ko­re­an drug­mak­er

6 years ago

In­cyte flips Chi­na rights of Macro­Gen­ic­s' PD-1 to an am­bi­tious Zai Lab keen on leapfrog­ging pi­o­neers with com­bos

6 years ago
China

Boehringer builds out NASH pipeline with up to $870M deal with South Ko­re­a's Yuhan

6 years ago

Se­duc­ing Pfiz­er: How Ar­ray’s team pa­tient­ly worked up the lad­der to win an $11.4B bid from Al­bert Bourla

6 years ago

Eye­ing a drug launch in ear­ly ’20, Es­pe­ri­on lines up a new, $200M fund­ing deal

6 years ago
R&D

Top an­a­lyst finds a sil­ver lin­ing in Ab­b­Vie’s $63B Al­ler­gan buy­out — but there’s a catch

6 years ago

The top 15 mega-deals in bio­phar­ma: Ab­b­Vie and Bris­tol-My­ers ac­qui­si­tions stir fresh de­bate over what's too big to buy

6 years ago

Ab­b­Vie's $63B buy­out spot­lights the re­turn of ma­jor M&A deals — de­spite the back­lash

6 years ago

Eye­ing a $500M peak sales pot, Almi­rall dou­bles down on le­brik­izum­ab as Der­mi­ra lines up PhI­II

6 years ago

Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

6 years ago

Gen­fit goes to Chi­na with a deal worth up to $228M for NASH drug

6 years ago
China

In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — just lat­er

6 years ago
First page Previous page 101102103104105106107 Next page Last page
A service from the Financial Times